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Abstract: Endocrine-disrupting chemicals (EDCs) are exogenous substances able to mimic or to
interfere with the endocrine system, thus altering key biological processes such as organ development,
reproduction, immunity, metabolism and behavior. High concentrations of EDCs are found in several
everyday products including plastic bottles and food containers and they could be easily absorbed
by dietary intake. In recent years, considerable interest has been raised regarding the biological
effects of EDCs, particularly Bisphenol A (BPA) and phthalates, on human pregnancy and fetal
development. Several evidence obtained on in vitro and animal models as well as by epidemiologic
and population studies strongly indicated that endocrine disruptors could negatively impact fetal
and placental health by interfering with the embryonic developing epigenome, thus establishing
disease paths into adulthood. Moreover, EDCs could cause and/or contribute to the onset of severe
gestational conditions as Preeclampsia (PE), Fetal Growth Restriction (FGR) and gestational diabetes
in pregnancy, as well as obesity, diabetes and cardiovascular complications in reproductive age.
Therefore, despite contrasting data being present in the literature, endocrine disruptors must be
considered as a therapeutic target. Future actions aimed at reducing or eliminating EDC exposure
during the perinatal period are mandatory to guarantee pregnancy success and preserve fetal and
adult health.
Keywords: endocrine-disrupting chemicals (EDCs); bisphenol A; phthalats; pregnancy; placenta;
diet; pregnancy pathologies
1. Introduction
Natural and man-made chemicals may mimic or interfere with the endocrine system, a complex
communication network among the nervous system and key biological functions such as reproduction,
immunity, metabolism and behavior [1]. These compounds—known as endocrine-disrupting chemicals
(EDCs)—are found in pesticides, metals and in several everyday products, including plastic bottles and
food containers, detergents, flame retardants, toys and cosmetics [2]. Due to their extreme diffusion
in everyday life, EDCs became object of intense investigation by the medical-scientific community,
mainly to clarify their role as risk factors and/or pathogenic triggers. Pregnancy is the most sensitive
clinical environment, where two lives, the mother and the developing embryo, could be simultaneously
affected by EDC activity. There are contrasting data in the literature about the immediate and long-term
effects of maternal and fetal EDC exposure.
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Therefore, the objective of this paper is to review the most recent findings on fetal–maternal
exposure to endocrine disruptors, particularly focusing on Bisphenol A (BPA) and phthalates, pregnancy
outcomes, the in-utero setting of post-natal and adult conditions as well as up-to-date guidelines to
reduce dietary EDCs exposure during the perinatal period.
2. Endocrine Disrupting Chemicals (EDCs)
According to the World Health Organization (WHO), an endocrine disruptor is “an exogenous
substance or mixture that alters function(s) of the endocrine system and consequently causes adverse
health effects in an intact organism, or its progeny, or (sub) populations” [3].
EDCs disrupt endocrine functions mainly by mimicking natural hormones like estrogens,
androgens or thyroid hormones. Moreover, they could alter hormones’ metabolism, thus blocking
and antagonizing their interaction with the specific membrane and/or intra-cellular receptors [2].
Almost 800 chemicals are suspected to interfere with endocrine functions [4]. For example, dioxins
are a byproduct in herbicide production, paper bleaching or in waste burning, while perchlorate is
a secondary product of aerospace, weapon and pharmaceutical industries frequently found in drinking
water [5,6]. Other EDCs are perfluoroalkyl and polyfluoroalkyl (PFAS), used in industrial applications
as firefighting foams and non-stick pans [7]. Phytoestrogens are natural endocrine disruptors occurring
in plants that have hormone-like activity, such as genistein and daidzein, that are in soy products like
tofu or soy milk [8]. Of particular interest are BPA and phthalates, widely investigated as “obesogenic”
factors that could interfere with pregnancy physiology and fetal development, thus being a leading
cause of reproductive disorders [4]. Fresh meat, fish and vegetables which are not packed in plastic
have a low concentration of BPA and phthalates [9], while ready-to-eat and fast food products stored
in plastic bags and cans are a major exposure source to these EDCs [10,11].
BPA is an industrial chemical obtained from condensation between phenol and acetone that has
been used to produce plastics and resins since the 1960s. It is considered the first synthetic estrogen
produced, although it does not possess a steroid structure since it does not include the phenanthrene
nucleus [12]. BPA is found in polycarbonate plastics that are commonly used in containers to store
food, beverages and other goods. It is also present in epoxy resins used to coat metal products
as food cans, bottle tops and water supply lines. Indeed, it is very easy to be exposed to BPA,
and since 2011 the European Union prohibited BPA use at least in polycarbonate baby bottles. BPA was
recently removed from many consumer products, being replaced by its structural analogs Bisphenol-S
(BPS) and Bisphenol-F (BPF). Nevertheless, BPS and BPF have detrimental effects similar to BPA,
such as cytotoxicity, genotoxicity, reproductive toxicity, dioxin-like effects and neurotoxicity. Moreover,
it has been shown that BPS and BPF exhibit estrogenic and/or anti-androgenic activities similar to
or even greater than those of BPA [13,14]. While studies investigating BPS and BPF metabolism are
lacking, BPA is absorbed by the digestive tract and, to a lesser extent, by the skin through direct
contact [15]. After ingestion, BPA is metabolized by the intestinal microbiota and by the liver, mainly by
glucuronidation and, to a lesser extent, sulfation, resulting in the production of BPA monoglucuronide
(BPA-G) and BPA sulphate (BPA-S), with BPA-G being the main BPA metabolite in humans [16].
The majority of BPA is metabolized to BPA-G via the Uridine 5′-diphospho-glucuronosyltransferase
(UGT) system. Studies on the fetal expression of UGT enzymes responsible for BPA glucuronidation
detected no to low enzyme activity during the prenatal period [17]. Nevertheless, the human fetus is
exposed to high BPA concentrations, since BPA-G and BPA-S are deconjugated and thus converted
back to BPA in the placenta [18].
BPA is well known for its estrogenic activity exerted through the activation of the Estrogen
Receptor (ER), with a stronger affinity for ERβ than for ERα, whereas BPA-G did not show ER-mediated
estrogenic activity [19], but it exerted pro-inflammatory effects via the competitive inhibition of PPAR-γ
signaling [20].
Phthalates are diesters of phthalic acid classified into high- and low-molecular-weight ones.
The first category includes several compounds that are largely adopted to increase plastic flexibility and
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durability. Among them, the most commonly employed additive is di (2-ethylhexyl) phthalate (DEHP).
Low-molecular-weight phthalates, like diethyl phthalate (DEP), are mainly used in personal care
products and cosmetics, but they could be also found in pesticides and in food packaging [21]. Exposure
to DEHP is reflected by the presence of its metabolites in urine, such as mono (2-ethylhexyl) phthalate
(MEHP), mono (2-ethyl-5-hydroxyhexyl) phthalate, mono (2-ethyl-5-carboxypentyl) phthalate and
mono(2-ethyl-5-oxohexyl) phthalate, whereas the main urinary metabolite of DEP is mono-ethyl
phthalate (MEP). Remarkably, the bioactivity of phthalate metabolites is superior to that of the original
substance [16].
BPA and phthalates are therefore widely present in everyday life due to the considerable volume
of plastic produced [22]. They could be released at room temperature but heating facilitates their
leaking out, resulting in massive food and beverage contamination [23]. For example, in polycarbonate
(PC) bottles, high temperatures stimulate BPA migration into water by promoting hydrolysis and/or
wall permeability [24], with a temperature that influences BPA migration more than heating time [25].
Table 1 summarizes the most important EDCs known to be disease risk factors.
Table 1. Endocrine-disrupting chemicals (EDCs) most relevant to human health.
EDC Metabolites Exposure Sources
Bisphenol [10]
Bisphenol A (BPA)
Bisphenol S (BPS)
Bisphenol F (BPF)
Bisphenol B (BPB)
[26]
BPA glucuronide (BPA-G)
BPA sulfate (BPA-S)
Synthetic [10]
Food packaging;
Thermal receipts;
Plastic dinnerware;
Polycarbonate plastic;
Epoxy resins;
Dental sealants;
High-Molecular-Weight Phathalate [10]
Di(2-ethylhexyl) phthalate (DEHP)
[10]
Mono(2-ethyl-5-hydroxyhexyl) phthalate;
mEHHP
Mono(2-ethylhexyl) phthalate; mEHP
Mono(2-ethyl-5-oxohexyl) phthalate;
mEOHP
Mono(2-ethyl-5-carboxypentyl) phthalate;
mECPP
Synthetic [10]
Food packaging and processing;
Pharmaceutical coatings;
PVC plastics;
Building materials;
Medical devices;
Low-Molecular-Weight Phathalate [10]
Diethyl phthalate (DEP)
[10]
Monoethyl phthalate; mEP
Synthetic [10]
Fragrant PCPs:|
perfumes/colognes;
deodorants;
soaps,
shampoos
lotions;
Persistent Organic Pollutants (POPs)
Dichlorodiphenyltrichloroethane (DDT) [27]
Dioxins (PCDD, PCDF) [5]
chlorodiphenyldichloroethylene (DDE)
Synthetic
Pesticides; [27]
Insecticide;
Combustion; [5]
Incineration;
Waste burning;
Paper bleaching;
Polycyclic Aromatic Hydrocarbons (PAHs) [27]
polybrominated diphenyl ethers (PBDEs)
polychlorinated biphenyls (PCBs)
brominated flame retardants (BFRs)
Synthetic [27]
Combustion processes;
Building materials;
Electronics furniture;
Hydraulic fluids;
Perfluorinated Alkylated Substances (PFAS) [7]
Perfluoroalkyl
Polyfluoroalkyl
Synthetic [7]
Personal care products:
Polishes and Paints;
Non-stick cookware;
Fire-fighting foams;
Phytoestrogens [8]
Isoflavonoids (Genistein, Daidzein)
Natural [8]
Soy beans and other legumes
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3. Exposure to BPA and Phthalates
Worldwide estimations of ECD daily intake based on urinary exposures revealed different exposure
levels across continents, countries, regions, and towns [28].
The globally estimated BPA daily intake in adults is 30.76 ng/kg bw/day, whereas a notably higher
daily intake, corresponding to 42.03 ng/kg bw/day, was found for pregnant women [29]. Both exposures
are below the tolerable daily intake (TDI) of 50 and 4 µg/kg bw/day recommended by both the U.S.
Environmental Protection Agency (US EPA) [30] and the European Food Safety Authority (EFSA) [31],
respectively. The highest exposures have been estimated for some European countries, including Italy,
while African countries seem to be the least exposed [29]. Over 90% of the overall BPA exposure
is thought to be due to diet, while the contribution of the non-dietary sources is less than 5% [32].
However, some authors consider that the non-dietary routes might be also important.
As regards phthalate daily intake, China’s adult population seems to be the most exposed [33],
with peaks of 60 µg/kg bw/day of DEHP in some coastal areas [34], a value three times higher than
the TDI of 50 µg/kg bw/day established by EFSA and the reference dose suggested by the US EPA of
20 µg/kg bw/day. Lower intake levels, within the safety ranges, were estimated for other regions of
China and for other countries [35–39]. In Italy, a daily intake of DEHP of 3.1 µg/kg bw was found
in Italian hospitalized adults [40]. Contaminated food is likely to be the largest route of exposure to
phthalate in the general population [41].
Although providing interesting data to identify populations at a greater exposure risk and to assist
policy makers in making regulations to reduce EDC exposure, one has to be aware of several pitfalls
when interpreting exposure to EDC based on urinary concentrations. First, the use of an equal body
weight for all populations risks overestimating exposure for some countries and underestimating it for
others. Second, BPA has been shown to accumulate in adipose tissue, affecting urinary excretion [42–45].
Thus, differences in the exposure to these EDC may exist because of the different body composition
between ethnic groups, ages and sexes. Third, the accuracy of estimates by region, country, or continent
depends on the number of studies available for each of them. While for some countries, such as the
USA and China, estimates are derived from dozens of studies investigating the ECDs exposure in the
population, for others, such as Italy, the estimate is derived from exposure found from one or, at most,
two studies.
All of this should be taken into consideration when estimating and interpreting the daily intake of
BPA and phthalates.
4. EDCs and Reproductive Health
4.1. Exposure to EDCs and Fertility
Human reproduction and pregnancy success depend on both female and male reproductive health
and EDCs, as BPA and phthalates could affect fertility of both genders.
The ovaries are responsible for female gametogenesis and endocrine functions during reproductive
life. It has been demonstrated that prenatal BPA exposure inhibited germ cell nest breakdown in F1
generation ovaries in mice, decreased the numbers of primordial, primary, preantral and total healthy
follicles at post-natal day 21 and decreased estradiol levels in female rats dosed for 1 year [46,47].
Hu and colleagues reported that sexually mature CD-1 mice treated by 5 consecutive BPA concentration
gradients (1, 10, 100, 1, and 10 mg/kg) for 28 days initiated the excessive premature activation of
primordial ovarian follicles via the PTEN/PI3K/AKT signaling pathway by downregulating PTEN
expression in vivo [48]. In a previous prospective cohort study, the association between urinary
BPA concentration and ovarian response among women undergoing in vitro fertilization (IVF) was
investigated. BPA was detected in the majority of IVF women and its urinary concentrations (ranging
from <0.4 to 25.5 mg/L) were inversely associated with number of retrieved oocytes per cycle and peak
levels of serum estradiol [49]. Moreover, a recent study on 700 Chinese couples attempting pregnancy
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revealed that women with the highest urinary BPA concentration (>2.33 ng/mL) had a 30% reduction
in fecundability and a 64% increase in the odds of infertility [33].
Phthalates were shown to disrupt female fertility by altering oocytes development and
maturation. Data are available from animal models. Adult CD-1 mice orally daily dosed with
DEHP (20–750 mg/kg/day) for 10 and 30 days showed a decreased percentage of primordial
follicles and an increased percentage of primary follicles, thus reducing reproductive lifespan.
The mechanism by which DEHP accelerates primordial follicle recruitment is likely via over-activation
of the phosphatidylinositol 3-kinase (PI3K) signaling, a pathway that regulates primordial follicle
survival, quiescence and recruitment. DEHP exposure increased ovarian mRNA levels of
3-phosphoinositide-dependent protein kinase-1 (Pdpk1), mammalian target of rapamycin complex
1 (Mtorc1), factors that drive primordial follicle recruitment, and decreased Phosphatase and tensin
homolog (Pten) and Tuberous sclerosis 1 (Tsc1) mRNA levels, promoters of primordial follicle
quiescence [50]. Prenatal DEHP exposure (0–40 µg/kg/day) significantly reduced percentage of
methylated CpG sites in Insulin-like growth factor 2 receptor (Igf2r) and Paternally expressed gene
3 (Peg3) differentially methylated regions (DMRs) in fetal primordial germ cells and in the oocytes
of the F1 mice. These DEHP-induced oocytes DNA methylation alterations were inherited by the F2
mice, indicating that DEHP effects on oocyte development are heritable [51]. MEHP, the active toxicant
DEHP metabolite, significantly reduced mouse oocyte viability at concentrations of 250 and 500 µM by
promoting oxidative stress. Overexpression of Cu–Zn superoxide dismutase (Sod1) and decreased
expression of mitochondrial respiratory chain protein (Nd1) were identified as possible molecular
mechanism leading to these MEHP-induced alterations in oocyte viability [52].
In males, EDCs exposure was associated with declined semen quality, increased sperm DNA
damage, alterations in testis morphology and endocrine function [20,53–55]. Mantzouki and colleagues
demonstrated that very high concentrations of plasma BPA (>3 ng/mL) were associated with
azoospermia in humans [56]. A cross-sectional study performed on 215 healthy young university
students (18–23 years old) revealed a significant positive association between urinary BPA concentrations
(2.8 (0.16–11.5) ng/mL) and serum LH levels as well as a significant and inverse association with sperm
concentration and the total sperm count, thus concluding that BPA exposure may be associated with
a reduction in Leydig cell capacity and decreased sperm counts in young men [57]. In accordance,
other studies demonstrated that urinary BPA levels (median 1.87 µg/L) were associated with decreased
sperm concentration and mobility, reduced semen quality, decreased antioxidant levels, reduced sperm
DNA integrity and increased percentage of immature sperm [58,59].
Even phthalates could negatively impact on male fertility. DEHP exposure (750 mg/kg/day) in
male CD-1 mice induced lower serum testosterone levels, accompanied by higher serum estradiol and
LH levels. Moreover, histological mice evaluations showed that male mice prenatally exposed to DEHP
were characterized by increased germ cell apoptosis, and the degeneration of seminiferous tubules,
oligozoospermia, asthenozoospermia, and teratozoospermia, leading to premature reproductive
senescence [60]. Yuan and colleagues described that DBP exposure (500 mg/kg) significantly decreased
sperm count in F1 through F3 generations. Specifically, they found global DNA hypomethylation
along with the hypomethylation of follistatin-like 3 (Fstl3) promoter, known modulator of Sertoli cell
number and spermatogenesis [61]. Recent evidence suggested that embryonic exposure to DEHP
(500 mg/kg body weight/day) could disrupt testicular germ cell organization and spermatogonia stem
cell function in a transgenerational manner. Specifically, DEHP treatment of pregnant CD1 outbred
mice at Embryonic Day 7 (E7) to E14 lead to disrupted testicular germ cell association, decreased sperm
count and motility in F1 to F4 offspring [62].
Therefore, EDCs as BPA and phthalates could have severe detrimental effects on human
reproduction, impairing both female and male fertility before pregnancy onset and causing gametes
anomalies during fetal development that could be inherited by the following generations.
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4.2. Exposure to EDCs during the Reproductive Age and Development of Obesity, Diabetes and
Cardiometabolic Abnormalities
The reproductive age is a critical phase in the life of a woman, as the development of certain
pathological conditions during this phase may influence the outcomes of future pregnancies.
The presence of obesity [63], diabetes [64–66] and cardiometabolic abnormalities [67,68], during
pregnancy has been associated with an increased risk of adverse maternal and fetal outcomes,
including gestational hypertension, preeclampsia, gestational diabetes, caesarean section, congenital
malformations, shoulder dystocia, perinatal death, preterm birth and large for gestational age at birth.
A pregnancy free of such comorbidities is, thus, the best situation to preserve the health of both mother
and child.
Nevertheless, the prevalence of obesity, diabetes and metabolic syndrome continuing to increase
worldwide [69]. Unhealthy dietary habits and a sedentary lifestyle are considered the big two causes
of such an increment, but there is a growing body of evidence suggesting a possible relationship
between exposure to EDC and cardiometabolic health [25]. It must be said that almost all epidemiologic
evidence on this issue comes from large cross-sectional studies and some cohort studies including
women of all ages, whereas the evidence of an association between the exposure to EDC during the
reproductive age and the risk of developing obesity, diabetes and cardiometabolic abnormalities is
limited to few, generally small, cross-sectional studies [70–73].
A small cross-sectional study involving 103 women aged 19–50 found that urinary BPA was
associated with BMI and, marginally, with waist circumference, after adjustment for energy intake and
energy requirement [70]. Similarly, another cross-sectional study, involving 246 healthy premenopausal
women with regular menstrual cycles, found that the urinary BPA was modestly associated with BMI,
waist circumference and fat mass assessed by DXA, after age-adjustment [71]. A third cross-sectional
study including 307 Korean women aged 30–49 years found the urinary BPA concentration was
associated with BMI, waist circumference, fasting insulin and HOMA index, but not with fasting glucose,
after adjustment for age, smoking status, alcohol status, triglyceride, total and HDL cholesterol levels.
Contrarily, urinary mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl)
phthalate (MEOHP) and mono-n-butyl phthalate (MNBP) concentrations were not associated with
any anthropometric and metabolic parameter [72]. Differently, the Shanghai Food Consumption
Survey (SHFCS) 2012–2014, including 1222 women, observed increased odds of central obesity in
women aged ≤ 45 years and with higher urinary levels of mono-2-ethylhexyl phthalate (MEHP) (OR
3.51, 95% CI 1.34, 7.00), MEOHP (OR 3.78, 95% CI 1.28, 8.72), MEHHP (OR 3.82, 95% CI 1.28, 8.84),
and mono-(2-ethyl-5-carboxypentyl)phthalate (MECPP) (OR 4.15, 95% CI 1.54, 8.58) compared to
women of the same age but with the lowest exposure [73].
At this stage, it is clear that it is not possible to draw conclusions on the relationship between
exposure to EDC during reproductive age and the risk of developing pathological conditions potentially
affecting pregnancy outcome. However, given the effect that obesity and metabolic complications can
have on the health of both mother and child, it is urgent to conduct epidemiological studies specifically
designed for this issue.
5. EDCs and Fetal Programming
The Developmental Origins of Health and Disease theory (DOHaD) introduced the concept
that maternal diet, environmental insults and lifestyle could significantly impact on fetal–placental,
development, thus establishing disease paths into adulthood [74,75]. In this context, endocrine
disruptors may play a leading role in fetal programming. It was previously reported that the placenta
is not such an effective barrier against EDCs and that pregnant women’s exposure was associated
with EDCs’ entrance in the fetal circulation [76–78]. Importantly, the developing fetus might be more
sensitive to EDCs than the adult [76] explaining why endocrine disruptors could adversely affect fetal
development with a particular impact on reproductive and hormonal systems. Epigenetic influences
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were implicated as mediators of the relationship between EDCs, environmental insults and health
status, while BPA and phthalates were indicated as sources of epigenetic disruption [79].
Epigenetics defines heritable phenotype changes that involve alterations in gene expression and not
in DNA sequence. Epigenetic mechanisms include DNA methylation, acetylation, genomic imprinting,
as well as the expression of microRNAs (miRNAs) and non-coding RNAs. These modifications
usually have an inhibitory effect on gene expression since they modulate DNA accessibility to
transcription factors and regulatory proteins by altering chromatin structure and/or by the recruitment
of histone modifiers. Early fetal development is particularly vulnerable to epigenetic insults since it is
characterized by a high DNA synthesis rate and because the complex machinery modulating DNA
methylation and chromatin organization is established at this time [80].
Studies investigating EDCs’ impact on fetal–placental epigenetics in early human pregnancy are
few due to the difficulties of collecting samples during the first trimester of pregnancy. Therefore, most
of the data available came from in-vitro and animal studies.
Data obtained on human fetal liver biopsies revealed that even low BPA doses could significantly
influence in-utero epigenetic regulation of xenobiotic metabolizing enzymes (XMEs), pivotal for
compounds metabolism and excretion. In particular, they described increased methylation at COMT
and SULT2A1 promoters related to higher BPA levels, anomalies that could alter disease susceptibility
later in life [81].
A recent cohort study reported the negative association among first-trimester maternal exposure
to BPA and phthalates and term cord blood methylation of imprinted (H19, IGF2) and non-imprinted
(PPARA, ESR1) genes and LINE-1 repetitive elements [82], epigenetic targets associated with growth,
development and metabolism. Of note, a sex-stratified analysis for DNA methylation revealed
that these EDC-induced effects were female-specific [82], confirming the epigenetics-related sexually
dimorphic effects of EDC exposure during prenatal development previously demonstrated in several
animal models [83]. A similar designed study was performed on 296 newborns from the CHAMACOS
Mexican–American longitudinal birth cohort. They specifically focused on fetal phthalates metabolites’
exposure during pregnancy, assessed on maternal urines, and their association with imprinted
genes DNA methylation quantified on cord blood samples at term. Interestingly, this investigation
demonstrated a significant positive association between phthalate metabolites concentration and the
methylation of Maternally Expressed 3 (MEG3) gene, known for its role in early growth, tumorigenesis
and metabolic processes [84].
Moreover, early life EDC exposure could affect obesity epigenetic programming through endocrine
disruptors’ ability to bind nuclear receptors as the Peroxisome Proliferator-Activated Receptor
(PPAR)γ, master regulator of adipogenesis modulating the expression of metabolic genes during
differentiation [85]. EDC-induced obesogenic effects are also accompanied by altered methylation
of PPARγ or PPARγ target genes [85]. Indeed, the relative expression of PPARγ-induced genes
during early development determines whether mesenchymal stem cells differentiate into osteocytes or
adipocytes, thus influencing body fat accumulation [86].
Another EDC target with important consequences for epigenetic regulation is the Estrogen
Receptor (ERα) [76,87]. ERα is a transcription factor whose activation triggers estrogen-responsive
elements present on the promoter region of the histone-lysine N-methyltransferase enzyme EZH2, key
player in gene silencing. It was recently reported that BPA and other estrogenic EDCs, by activating
Estrogen Receptors and ERs coregulators Mixed Lineage Leukemia histone methylases (MLL2 and
MLL3) and histone acetyltransferase CBP/P300, increase the expression of EZH2 [88], thus potentially
affecting global epigenetic regulation, even during in-utero development.
Even the placenta is directly affected by EDC activity. Studies conducted in mice demonstrated that
BPA intrauterine exposure markedly altered the placental methylation of imprinted genes [89] affecting
placental loss-of-imprinting and decreasing both global and CpG-specific DNA methylation [90].
Furthermore, it was reported in the HTR8/SVneo human cytotrophoblast cell line that BPA exposure
negatively affected cytotrophoblast invasion through the hypermethylation and downregulation of the
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WNT2 gene via DNA (cytosine-5)-methyltransferase 1 (DNMT1), with a negative correlation confirmed
also in BPA-induced preeclamptic-like mouse placentae [91]. The BPA-substitute BPS was reported to
alter the placental expression of the efflux transporter P-glycoprotein (P-gp), one of the main regulators
of fetal exposure to xenobiotics encoded by the ABCB1 gene. Using CRL-1584 human trophoblast cell
lines, Speidel and colleagues demonstrated that acute exposure to BPS (0.5 nM) induced a significant
haplotype-dependent decrease in ABCB1 promoter activity, while chronic BPS exposure (0.3 nM)
induced a significant haplotype-dependent promoter activity increase, thus dramatically impacting on
P-gp levels and fetal exposure to xenobiotics coming from the maternal circulation [92]. Moreover,
prenatal exposure to BPS (5 mg/kg/d) in C57BL/6 N mice was described to increase the susceptibility to
high-fat-diet-induced adipogenesis in F1 male adult mice via the upregulation of PPAR-γ and its target
genes [93]. Finally, the epidermal growth factor receptor (EGFR) was identified as a key mediator of
phthalates effects on early placental function among a group of 39 first-trimester placental genes with
altered methylation after high phthalate exposure [94].
Indeed, different EDCs types such as BPA and phthalates have specific gene targets and their
actions could be influenced by fetal sex. Importantly, so-called safer alternatives to BPA as BPS
could have detrimental effects on fetal programming too. These data open new perspectives into the
understanding of EDCs’ influence on the prenatal development of adult health susceptibilities and
pregnancy-related disorders.
6. EDCs and Placenta-Related Conditions
Beside impacting on epigenetic switches and fetal programming, BPA and phthalates could
directly alter pregnancy physiology, undermining its success. As reported for EDC-induced epigenetic
modifications, most of the mechanistic data present in the literature about endocrine disrupting
chemicals and human pregnancy disorders derive from animal and in vitro data.
Starting from the very beginning of gestation, EDCs were recognized as potent perturbators of
human Chorionic Gonadotropin (hCG) production and secretion [95]. hCG is a hormone specifically
produced by the syncytiotrophoblast whose major functions are crucial for pregnancy establishment as
it induces ovulation, maintenance of the corpus luteum and progesterone production during the first
9 weeks of gestation [95]. In vitro studies on trophoblast cell lines and human chorionic villous explants
demonstrated that very low BPA concentrations increased hCG secretion and reduced extravillous
trophoblast migration and invasion [96,97], early modifications typical of severe pregnancy-related
syndromes such as Preeclampsia (PE).
PE is a major cause of mortality and morbidity worldwide, complicating 3 to 8% of all
pregnancies and characterized by maternal hypertension and multiorgan damage. It originates
during early gestation and, despite its etiopathogenesis remaining unclear, it is widely accepted
that a placental/systemic vascular dysfunction characterized by an imbalance between pro- and
anti-angiogenic factors such as placental growth factor (PlGF) and soluble fms-tyrosine kinase
(sFlt)−1 underlie PE onset.
In a recent population-based prospective cohort study including 1233 women, a positive association
was reported between increased first-trimester urine high molecular weight phthalates metabolites
and a higher sFlt-1/PlGF ratio, parameter used for PE screening [98]. However, the authors did not
find consistent associations among early pregnancy EDCs metabolite concentrations and maternal
prenatal blood pressure, placental hemodynamic outcomes or gestational hypertensive disorders [98].
In line with these results, it was previously shown that maternal urine BPA and DEHP metabolites are
associated with an increased maternal plasma sFlt-1/PlGF ratio, where BPA specifically induced sFlt-1
increase, while DEHP accounted for PlGF decrease [99].
Among the proposed mechanisms by which EDCs could lead to PE, the disruption of normal
placental development plays a major role. A pregnant mouse model exposed to a BPA minimum
effective dose of 4 µmol/L developed preeclampsia-like features such as hypertension, abnormal
circulating and placental sFlt-1/PlGF levels and kidney damage [91]. The BPA-induced PE phenotype
Nutrients 2020, 12, 1744 9 of 19
was accompanied by decreased trophoblast invasion, increased expression of metalloproteinases
inhibitors TIMP-1/2 and DNA methylation transferase-1 (DNMT-1) and decreased expression of
metalloproteinases MMP-2/9, β-catenin and WNT-2, key cell fate regulator. Of note, the BPA-related
reduced expression of WNT-2 was correlated with increased DNA methylation in its promoter
region [91].
Preeclampsia is often associated with Fetal Growth Restriction (FGR) defined as failure of the
fetus to achieve its genetically determined growth potential [100]. DEHP exposure during pregnancy
(50–200 mg/Kg) was demonstrated to induce FGR by disrupting placental thyroid hormone receptor
(THR) signaling in mice [101]. The DEHP-FGR mice were also characterized by the down-regulation
of THR downstream genes such as Vegf, Pgf, Igf1 and Igf2, pivotal for placental angiogenesis [101].
Other EDCs, such as fenvalerate, a widely used type II pyrethoid pesticide, were reported to induce
FGR by impairing THRs pathways [102]. Specifically, maternal fenvalerate exposure down-regulated
TRalpha1 and TRbeta1 placental expression and it repressed the nuclear translocation of placental
TRbeta1 in mice [102]. These results are in agreement with increasing evidence demonstrating the
important role of thyroid hormone receptor signaling in the preservation of placental function and
fetal development [103,104].
Even BPA exposure was linked to FGR development. In a recent work, a considered safe dose of
BPA (50 µg/kg BPA/day) was administered to pregnant mice during the implantation window (day 1 to
7 of gestation), thus inducing defective remodeling of maternal spiral arteries by placental trophoblast
with consequent intrauterine growth restriction [105].
The deleterious EDCs effects on physiological pregnancy development were also demonstrated in
in vitro human placental models and population studies, even though contrasting data are present
in the literature. MEHP inhibited trophoblast invasion by activating the PPARγ pathway in human
HTR-8/SVneo extravillous trophoblast cell lines, mechanisms associated with early pregnancy loss [106].
A prospective birth cohort investigation performed on 788 mother–child pairs in the third trimester in
Korea concluded that BPA exposure was negatively associated with intrauterine linear growth and
affected by maternal glutathione transferases polymorphisms [107], while previous studies reported
no association between exposure to BPA and birth weight [108].
In conclusion, despite controversial evidence in epidemiologic, in vitro and animal studies, there
is a general consensus on the harmful effects of EDC exposure during fetal life. Several molecular
mechanisms have been proposed to explain the role of BPA and phthalates in the onset of severe
pregnancy-related conditions such as PE and FGR, suggesting as a main outcome an aberrant placental
development. Most of the differences in the literature results and interpretations are probably due to
an extreme variability in EDC types and concentrations used, time of administration, for animal or
in vitro models, or sampling windows for human gestation studies.
7. EDCs and Gestational Diabetes
It is well known that even during a healthy pregnancy, the release of numerous placental hormones
promotes insulin-resistance, which is addressed through a compensatory insulin secretion by the
pancreatic β-cells [109]. Gestational diabetes (GDM) occurs when pregnant women have dysfunctional
β-cells, unable to balance the increased requirements of insulin [110].
Excessive weight gain during pregnancy is a risk factor for GDM. Some recent studies
suggest a possible link between the gestational exposure to EDCs and weight gain in pregnancy.
In a population-based prospective cohort study among 1213 pregnant women, each log unit increase in
early pregnancy BPA and di-n-octylphthalate urine concentrations were associated with lower mid-to
late pregnancy gestational weight gain (−132 g/log unit increase [95% CI −231, −34] and −176 g/log
unit increase [95% CI −324, −29]) [111]. Differently, in the LIFECODES pregnancy cohort, 347 pregnant
women were recruited, and the 1st-trimester urinary phthalate metabolite concentrations were related
to early gestational weight gain (median time period: 7.4 gestational weeks). The association between
MEP and gestational weight gain followed a U-shape with increasing gestational weight gain in
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the second quartile compared to the lowest one (difference 1.3 kg, 95% CI: 0.3–2.4). Differently,
the dose–response association between DEHP and gestational weight gain was described by an inverse
U-shape [112].
In a Chinese cohort prospective study including 620 pregnant women, plasma glucose at 2 h
in the 75-g OGTT was 0.36 mmol/L lower (95% CI −0.73, 0.01) for women with urine BPA in the
high versus the low tertile, and for each log unit increase, the odds of GDM was reduced by 27%
(OR 0.73, 95% CI 0.56, 0.97) [113]. On the contrary, in a small case-control study, no evidence of
association between BPA exposure and GDM diagnosis across increasing tertiles of BPA exposure was
found [114]. No statistically significant associations were observed between first-trimester urinary BPA
concentration with diagnosis of impaired glucose tolerance (IFG) or GDM even in the Maternal-Infant
Research on Environmental Chemicals (MIREC) cohort study [115]. The latter study also failed to find
an association between urinary concentration of phthalates metabolites and risk of IFG and GDM [115].
Contrary, in the LIFECODES pregnancy cohort, second-trimester MEP exposure was associated with
increased odds of IGT (OR 7.18, 95% CI 1.97, 26.15). DEHP concentration was inversely associated with
IGT (OR 0.25, 95% CI 0.08, 0.85). In both cases, the confidence intervals were very wide, suggesting low
accuracy of the risk estimates [116]. In “The Infant Development and Environment Study” (TIDES),
which included 705 pregnant women, the averaged first and third trimester urinary MEP concentration
was associated with increased odd of GDM (OR 1.61, 95% CI 1.10, 2.36), whereas first-trimester urinary
mono-(3-carboxypropyl) phthalate (MCPP) concentration was inversely associated (OR 0.64 95%
CI 0.43, 0.96). Only the averaged first- and third-trimester urinary mono-n-butylphthalate (MNBP)
concentration was associated with the risk of IGT (OR 1.32, 95% CI 1.00, 1.75) [117]. In a small
cross-sectional study, women with the highest urinary concentrations of mono-iso-butyl phthalate
(MIBP) and mono-benzyl phthalate (MBZP) had lower blood glucose levels at the time of GDM
diagnosis compared to women with lower urinary concentrations of such phthalates metabolites [118].
In conclusion, the limited evidence and conflicting results do not allow a definitive conclusion.
The discrepancies in the literature results are presumably due to the different time windows considered
for the exposure assessment, the use of a single-spot urine sampling to assess exposure, the different
criteria used to diagnose GDM, and not considering pre-gestational exposure.
8. Guidelines to Reduce Dietary Exposure to EDCs
Although there is an urgent need to have data on the association between the level of EDCs in
reproductive age and pregnancy outcomes, it is well known that dietary exposure is relevant. There
can be substantial variability in phthalate concentrations within food groups based on the region of
food production, processing practices, presence and type of packaging and lipid content [119,120].
Recent reviews of the food monitoring and epidemiology data revealed that foods of animal origin are
major sources of phthalates, partially because they are slightly lipophilic and can bioaccumulate in
fat-containing foods [10,121]. Poultry, some dairy products (cream) and fats are routinely contaminated
with higher concentrations of phthalates than other foods [121]. Detectable concentrations of
phthalates and BPA are in seafood products, especially if frozen or canned [10], and consuming
them ≥1–3 times/week making it a major source of BPA during pregnancy [122]. By contrast, milk,
yogurt and eggs were found to contain low concentrations of phthalates as a whole [121]. Concerning
vegetable foods, fruit and vegetables products in jars contain high concentrations of phthalates, while
fresh fruits and vegetables, pasta, noodles, rice are associated with lower exposures [10].
8.1. Perfluorinated Compounds (PFCs): PFOS and PFOA
According to the EFSA Panel on Contaminants in the Food Chain, some foods (especially seafood)
are an important source of exposure to PFCs. Moreover, PFOA has been used in the past in the
production of non-stick coatings. Currently, Italian manufacturers of cookware coatings do not use
products with PFOA. Therefore, consumers have to turn their attention to products coming from
non-European countries, especially those without the CE mark [123].
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8.2. Di(2-Ethylhexyl)-Phthalate (DEHP)
Food contact materials (film, blister packaging, screw caps, bottles, trays and transport packaging)
are the main dietary sources of DEHP. However, DEHP use in Europe has dramatically dropped;
for some usages, such as flooring and food contact film, European manufacturers have almost
completely substituted and phased-out DEHP [123].
8.3. Polycyclic Aromatic Hydrocarbons (PAHs)
PAHs are a group of compounds that are formed from combustion processes, both industrial and
household. Nutrition plays a key role in the prevention of exposure: PAHs form at high temperatures
within overheated parts of foods, especially with some cooking methods, such as grilling or charring,
smoking, or barbecuing [123].
8.4. BPA
As mentioned above, BPA is a chemical «building block» for the manufacture of polycarbonate
plastic used in food contact materials and epoxy resins (lining protective of most cans and food
recipients). Canned foods and beverages are the main source of dietary exposure for all age groups,
and consumers may be exposed to either the residual monomer that migrates from cans to beverages
and foods, or the products that result from polymer hydrolysis [123].
Table 2 summarizes the practical arrangements for food selection, cooking and storage
elaborated by the National Institute of Health [123] and integrated with other recent epidemiological
findings [122–125] to reduce dietary exposure to EDCs during reproductive age and the risk of
developing pathological conditions that may compromise a future pregnancy.
Table 2. Guidelines to reduce dietary exposure to EDCs.
Food Selection
1. Prefer fresh seasonal food, especially fish, fruits and vegetables;
2. Reduce the consumption of canned fish or frozen seafood to once a week;
3. Buy your tomato sauce and legumes in glass jars;
4. Purchase beverages in plastic or glass bottles. Prefer tap water if possible: visit the website of your
municipality to learn more about its characteristics;
5. Avoid ready-made food as “heat-and-go” cups or instant soups;
6. Prefer pizza or sandwich without boxes or wrappers but displayed freshly at the counter;
7. Reduce the use of popcorn bags for microwave cooking, choosing stovetop alternatives;
8. Replace a plastic coffee maker using a French press or ceramic drip;
9. Avoid plastic tea bags and purchase tea from manufacturers who can certify that their tea bags do not
contain EDCs. It is preferable to opt for loose tea;
10. Avoid the consumption of partially charred/burned foods, removing burned parts (i.e., meat or pizza).;
11. Limit smoked foods to once a month.
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Table 2. Cont.
Cooking
12. Avoid heat and use only undamaged containers to heat food and beverages and only for the uses
specified by the manufacturer;
13. Do not put polycarbonate plastics in the microwave. Use glass, porcelain or stainless-steel containers for
hot foods and liquids in place of plastic containers;
14. Remove the fatty portion of meat before cooking: reduce barbecuing or grilling, especially those over
charcoal, preferring other cooking methods;
15. Phase out the use of worn non-stick cookware, even to ensure cooking without charring/carbonization.
Turn your attention to products coming from non-European countries, especially those without the
CE mark;
16. When cooking, ensure a proper ventilation in the room and use an appropriate kitchen range hood.
Storage
17. Use dishwasher only for plastic containers suitable for high temperatures;
18. Do not reuse worn out plastic containers for food and beverages;
19. Let hot food and beverages cool before pouring in plastic containers not suitable for high temperatures;
20. Use grease-proof paper or film for food packaging (e.g., cling film) only following the manufacturer’s
instructions. Read the product’s label;
21. When choosing home materials, limit the use of soft PVC containing DEHP. Prefer BPA-and
phthalates-free products.
9. Concluding Remarks
Endocrine-disrupting chemicals represent a health threat that should not be underestimated,
especially when dealing with human pregnancy. Pregnant women can be easily exposed to
a large number of EDCs by dietary intake. Because of their biochemical features, EDCs pass the
placental barrier and reach the developing fetus, causing aberrant genetic/epigenetic regulation with
sex-specific modifications and contributing to the onset of placenta- and pregnancy-related disorders.
The medical-scientific community has still a lot of work to do in order to clarify the pathways involved
in EDCs’ effects on pregnancy physiology. The main limitation that explains the contrasting results
present in the literature is the high variability in experimental conditions and models used to investigate
EDC activity in the perinatal period. Therefore, a great effort must be made by researchers in the field
to set up common protocols and guidelines in order to improve data reliability.
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